Genomic Biomarkers Market

The genomic biomarkers market is expected to reach USD 50.31 billion by 2030, from USD 29.00 billion in 2025, reporting a CAGR of 11.6% between 2025 and 2030. Several key factors, including the growing use of genomic testing in oncology, rare diseases, and inherited disorders, and rapid advancements in NGS, PCR, and multi-omics technologies, drive the growth of the genomic biomarkers market.

To know about the assumptions considered for the study download the pdf brochure

Several key players in the genomic biomarkers market include Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Luxembourg), and Quanterix (US), among others. Companies in this space are pursuing expansion strategies to strengthen their global footprint and advance their technology portfolios. In August 2024, Illumina announced that the US Food and Drug Administration (FDA) had approved its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test. The test also received approval for its first two companion diagnostic (CDx) indications.

Thermo Fisher Scientific Inc. (US)

The Oncomine portfolio and the Genexus sequencing system from Thermo Fisher Scientific make it a prominent player in the genomic biomarkers market, enabling comprehensive genomic profiling on a single platform for clinical labs. The current assays on this platform cover essential DNA and RNA biomarkers in solid tumors and hematologic malignancies, aiding oncologists in quickly selecting targeted and immunotherapy treatments. The integration of sample-to-report processes, fast turnaround times, and collaborations with pharma for companion diagnostic purposes, along with compatibility with current hospital and regional laboratory infrastructure, makes it easier for them to adopt such cutting-edge biomarker tests within their settings rather than depending on reference labs.

F. Hoffmann-La Roche AG (Switzerland)

Roche, one of the leading players in the field of genomic biomarker testing for oncology, offers FoundationOne CDx and FoundationOne Liquid CDx, comprehensive genomic profiling tests that are tissue-based and liquid biopsies, respectively. The tests can analyze hundreds of relevant genes, fusions, and genomic signatures at once and relate them to approved and investigated therapies and clinical trials. Roche, in collaboration with its pharmaceutical and regulatory expertise and its global network of laboratories, is committed to standardizing biomarker testing, making precision oncology more accessible, and generating real-world evidence that informs the entire drug development and reimbursement process.

Illumina  (US)

Illumina is a significant force in the genomic biomarkers industry, with its sequencing solutions, reagents, and the TruSight Oncology Comprehensive testing menu, which enables comprehensive cancer panels and companion diagnostics on a single platform with the same underlying architecture. Cancer institutes and referral labs use Illumina's solutions to measure genomic variants, tumor mutational burden, and more complex biomarkers, which inform decisions about targeted therapy, immuno-oncology treatments, and clinical trial enrollment. By integrating FDA-approved IVD tests, research-use-only solutions, and successful collaborations with its diagnostic partners, Illumina remains at the forefront of developing standardized next-generation sequencing procedures and supporting the transition toward high-throughput, data-intensive biomarker testing.

Market Ranking

The genomic biomarkers market is characterized by significant consolidation, with a few large companies establishing technology standards and influencing test adoption in clinical oncology. Thermo Fisher Scientific (US) offers a broad Oncomine NGS portfolio and the Genexus integrated sequencer, providing rapid, end-to-end comprehensive genomic profiling solutions that fit both high-throughput reference labs and regional cancer centers. F. Hoffmann-La Roche (Switzerland) provides tissue and liquid-biopsy CGP assays such as FoundationOne CDx and FoundationOne Liquid CDx, linking genomic biomarker data to approved targeted and immunotherapies across multiple tumor types. Illumina (US) offers sequencing platforms and TruSight Oncology Comprehensive IVD solutions, enabling hospitals and national testing networks to run large pan-cancer biomarker panels on a standardized NGS backbone, supporting both routine diagnostics and large-scale precision medicine programs.

Related Reports:

Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com